Jeff Cohen
Stock Analyst at Ladenburg Thalmann
(2.26)
# 847
Out of 5,291 analysts
23
Total ratings
66.67%
Success rate
31.75%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Beta Bionics | Initiates Coverage On: Buy | 31 | 11.71 | 164.73% | 1 | Feb 20, 2025 | |
Legacy Education | Maintains: Strong Buy | 10 11 | 7.21 | 49.79% | 2 | Feb 14, 2025 | |
Bionano Genomics | Downgrades: Neutral | n/a | n/a | n/a | 1 | Nov 15, 2024 | |
Sonoma Pharmaceutica... | Initiates Coverage On: Buy | 65 | 2.4 | 2608.33% | 1 | Sep 5, 2023 | |
Healthcare Capital | Initiates Coverage On: Buy | 18 | n/a | n/a | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 52 | 35.31 | 47.27% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 130 | 130.94 | -0.72% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 110 130 | 210.43 | -38.22% | 3 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 72 78 | n/a | n/a | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underweight | 6 4 | n/a | n/a | 2 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | n/a | n/a | n/a | 3 | Jan 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Equal-Weight | 60 | n/a | n/a | 1 | Dec 18, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | n/a | n/a | 1 | Dec 18, 2019 |